Sterling IMRES
Sign in
Research articleOpen access

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

New England Journal of Medicine · 26 November 2015

Read at the publisher
Reference library record. This work was written and published by the people and publisher named here. It is listed in the Sterling IMRES reference library for study and citation. Sterling IMRES did not author or publish it, and listing a work does not mean its authors are affiliated with the institute. Metadata verified via Crossref. How records are verified

Summary

Reports the EMPA-REG OUTCOME randomized trial of empagliflozin versus placebo in people with type 2 diabetes and established cardiovascular disease. The trial was one of the first to show cardiovascular benefit from a glucose-lowering drug, and it helped reshape treatment of diabetes in patients at high cardiovascular risk.

Summary written by Sterling IMRES editors. Read the original abstract at the publisher.

Authors

Cite this work

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373(22):2117-2128. doi:10.1056/NEJMoa1504720

Related publications